Type 2 biomarkers associated with dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma enrolled in the phase 3 study LIBERTY ASTHMA QUEST by Wenzel, SE, Pavord, I, Zhang, B, Maroni, J, Rowe, P, Hamilton, JD, Swanson, BN, Amin, N, Pirozzi, G, Graham, NM, Teper, A

Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial by Corren J, Saini SS, Gagnon R, Moss MH, Sussman G, Jacobs J, Laws E, Chung ES, Constant T, Sun Y, Maloney J, Hamilton JD, Ruddy M, Wang CQ, O’Brien MP

Get full text